St. John's Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier
- PMID: 20229133
- DOI: 10.1007/s11095-010-0074-1
St. John's Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier
Abstract
Purpose: The purpose of this study was to investigate the short-term signaling effects of St. John's Wort (SJW) extract and selected SJW constituents on the blood-brain barrier transporter P-glycoprotein and to describe the role of PKC in the signaling.
Methods: Cultured porcine brain capillary endothelial cells (PBCEC) and freshly isolated brain capillaries from pig were used as in vitro/ex vivo blood-brain barrier model. SJW modulation of P-glycoprotein function was studied in PBCEC using a calcein-AM uptake assay and in isolated pig brain capillaries using the fluorescent cyclosporine A derivative NBD-CSA and confocal microscopy.
Results: SJW extract and the constituents hyperforin, hypericin, and quercetin decreased P-glycoprotein transport activity in a dose- and time-dependent manner. SJW extract and hyperforin directly inhibited P-glycoprotein activity, whereas hypericin and quercetin modulated transporter function through a mechanism involving protein kinase C. Quercetin at high concentrations decreased P-glycoprotein transport activity, but increased transporter function at low concentrations. This increase in P-glycoprotein activity was likely due to trafficking and membrane insertion of vesicles containing transporter protein.
Conclusions: Our findings provide new insights into the short-term interaction of SJW with P-glycoprotein at the blood-brain barrier. They are of potential relevance given the wide use of SJW as OTC medication and the importance P-glycoprotein has for CNS therapy.
Similar articles
-
Modulation of P-glycoprotein function by St John's wort extract and its major constituents.Pharmacopsychiatry. 2004 Nov;37(6):292-8. doi: 10.1055/s-2004-832686. Pharmacopsychiatry. 2004. PMID: 15551196
-
Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.J Pharm Pharmacol. 2004 Jan;56(1):123-8. doi: 10.1211/0022357022395. J Pharm Pharmacol. 2004. PMID: 14980009
-
Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.Br J Pharmacol. 2001 Dec;134(8):1601-8. doi: 10.1038/sj.bjp.0704399. Br J Pharmacol. 2001. PMID: 11739235 Free PMC article.
-
Clinical risks of St John's Wort (Hypericum perforatum) co-administration.Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1047-1062. doi: 10.1080/17425255.2017.1378342. Epub 2017 Sep 13. Expert Opin Drug Metab Toxicol. 2017. PMID: 28885074 Review.
-
Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions.J Ethnopharmacol. 2017 Mar 22;200:136-146. doi: 10.1016/j.jep.2017.02.016. Epub 2017 Feb 12. J Ethnopharmacol. 2017. PMID: 28216196 Review.
Cited by
-
St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein.Brain Pathol. 2014 Jan;24(1):18-24. doi: 10.1111/bpa.12069. Epub 2013 Jun 28. Brain Pathol. 2014. PMID: 23701205 Free PMC article.
-
St. John's Wort Extract Increases Pgp Expression in the Brain but Not in the Small Intestine or the Liver of Wistar Rats.Pharmacol Res Perspect. 2025 Jun;13(3):e70111. doi: 10.1002/prp2.70111. Pharmacol Res Perspect. 2025. PMID: 40325522 Free PMC article.
-
Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial.Anesthesiology. 2020 Mar;132(3):491-503. doi: 10.1097/ALN.0000000000003065. Anesthesiology. 2020. PMID: 31794512 Free PMC article. Clinical Trial.
-
Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management.Mol Divers. 2014 Nov;18(4):895-909. doi: 10.1007/s11030-014-9550-6. Epub 2014 Sep 12. Mol Divers. 2014. PMID: 25213397 Review.
-
Drug interactions with herbal medicines.Clin Pharmacokinet. 2012 Feb 1;51(2):77-104. doi: 10.2165/11597910-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22257149 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources